| Schedule of Revenue Recognized in Unaudited Condensed Consolidated Interim Statements of Profit or Loss |
Revenue has been recognized in the unaudited condensed consolidated interim statements of profit or loss in the following amounts:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
September 30, |
|
|
Nine Months Ended
September 30, |
|
|
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
|
|
(EUR’000) |
|
|
(EUR’000) |
|
Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
Commercial products |
|
|
55,710 |
|
|
|
46,968 |
|
|
|
153,598 |
|
|
|
114,414 |
|
Rendering of services |
|
|
1,272 |
|
|
|
401 |
|
|
|
9,636 |
|
|
|
12,480 |
|
Clinical supply |
|
|
— |
|
|
|
94 |
|
|
|
1 |
|
|
|
348 |
|
Licenses |
|
|
851 |
|
|
|
571 |
|
|
|
26,490 |
|
|
|
1,774 |
|
Total revenue |
|
|
57,833 |
|
|
|
48,034 |
|
|
|
189,725 |
|
|
|
129,016 |
|
Attributable to |
|
|
|
|
|
|
|
|
|
|
|
|
Commercial customers |
|
|
55,710 |
|
|
|
46,968 |
|
|
|
153,598 |
|
|
|
114,414 |
|
Collaboration partners and license agreements |
|
|
2,123 |
|
|
|
1,066 |
|
|
|
36,127 |
|
|
|
14,602 |
|
Total revenue |
|
|
57,833 |
|
|
|
48,034 |
|
|
|
189,725 |
|
|
|
129,016 |
|
Specified by timing of recognition |
|
|
|
|
|
|
|
|
|
|
|
|
Recognized over time |
|
|
1,272 |
|
|
|
401 |
|
|
|
9,636 |
|
|
|
12,480 |
|
Recognized at a point in time |
|
|
56,561 |
|
|
|
47,633 |
|
|
|
180,089 |
|
|
|
116,536 |
|
Total revenue |
|
|
57,833 |
|
|
|
48,034 |
|
|
|
189,725 |
|
|
|
129,016 |
|
Specified per geographical area |
|
|
|
|
|
|
|
|
|
|
|
|
Europe |
|
|
8,151 |
|
|
|
381 |
|
|
|
14,800 |
|
|
|
381 |
|
North America |
|
|
48,758 |
|
|
|
47,234 |
|
|
|
170,833 |
|
|
|
127,059 |
|
Rest of world |
|
|
924 |
|
|
|
419 |
|
|
|
4,092 |
|
|
|
1,576 |
|
Total revenue |
|
|
57,833 |
|
|
|
48,034 |
|
|
|
189,725 |
|
|
|
129,016 |
|
|